Per Business Quant data, ZyVersa Therapeutics insiders hold 1.53K shares in total based on their latest Form 4 filings, or 0.02% of the 8.1Mn shares outstanding; that total is unchanged from the end of Q2 2026 and Q3 2025.
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Daniel J. O'Connor | Director, TenPercentOwner | 0 | 4,632 | 4,632 | 29.0% | 14 Dec, 2022 |
| 2 | Co., Ltd. Incon | TenPercentOwner | 4,278 | 0 | 4,278 | 26.8% | 16 Dec, 2022 |
| 3 | Health Llc Larkspur | TenPercentOwner | 3,936 | 0 | 3,936 | 24.6% | 10 Mar, 2022 |
| 4 | Stephen C. Glover | Chief Executive Officer | 1,283 | 125 | 1,408 | 8.8% | 14 Dec, 2022 |
| 5 | / Alliance Global Partners Corp. A.G.P. | TenPercentOwner | 1,277 | 0 | 1,277 | 8.0% | 08 Mar, 2022 |
| 6 | David S. Briones | Chief Financial Officer | 0 | 191 | 191 | 1.2% | 10 Mar, 2022 |
| 7 | Peter Wolfe | Chief Financial Officer | 127 | 0 | 127 | 0.8% | 20 Dec, 2022 |
| 8 | Nicholas A. Jr. Labella | Chief Scientific Officer | 52 | 0 | 52 | 0.3% | 14 Dec, 2022 |
| 9 | Raj Mehra | Director | 25 | 0 | 25 | 0.2% | 10 Mar, 2022 |
| 10 | Christopher Twitty | Director | 25 | 0 | 25 | 0.2% | 10 Mar, 2022 |
| 11 | Gregory Skalicky | Director | 25 | 0 | 25 | 0.2% | 10 Mar, 2022 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 11 Jul, 2025 | Karen A. Cashmere | Chief Commercial Officer | Acquired A | 48,100 | $0.00 | $0 | 48,100 | Direct |
| 11 Jul, 2025 | Peter Wolfe | Chief Financial Officer | Acquired A | 60,100 | $0.00 | $0 | 60,100 | Direct |
| 11 Jul, 2025 | Pablo A. Guzman | Chief Medical Officer | Acquired A | 48,900 | $0.00 | $0 | 48,900 | Direct |
| 11 Jul, 2025 | Stephen C. Glover | Chief Executive Officer | Acquired A | 136,900 | $0.00 | $0 | 136,900 | Direct |
| 11 Jul, 2025 | Gregory Gene Freitag | Director | Acquired A | 11,066 | $0.00 | $0 | 11,066 | Direct |
| 11 Jul, 2025 | Min-Chul Park | Director | Acquired A | 11,066 | $0.00 | $0 | 11,066 | Direct |
| 11 Jul, 2025 | Robert G Finizio | Director | Acquired A | 11,066 | $0.00 | $0 | 11,066 | Direct |
| 11 Jul, 2025 | James Sapirstein | Director | Acquired A | 11,066 | $0.00 | $0 | 11,066 | Direct |
| 26 Jan, 2023 | Pablo A. Guzman | Chief Medical Officer | Acquired A | 100,000 | $0.00 | $0 | 286 | Direct |
| 16 Dec, 2022 | Peter Wolfe | Chief Financial Officer | Acquired A | 3,000 | $1,008.58 | $3.03Mn | 127 | Direct |
| 12 Dec, 2022 | Co., Ltd. Incon | TenPercentOwner | Acquired A | 1,497,199 | $0.00 | $0 | 4,278 | Direct |
| 12 Dec, 2022 | Co., Ltd. Incon | TenPercentOwner | Acquired A | 450,702 | $0.00 | $0 | 1,288 | Direct |
| 12 Dec, 2022 | Nicholas A. Jr. Labella | Chief Scientific Officer | Acquired A | 18,094 | — | — | 52 | Direct |
| 12 Dec, 2022 | Daniel J. O'Connor | Director, TenPercentOwner | Acquired J | 1,377,598 | $0.00 | $0 | 3,936 | Indirect |
| 12 Dec, 2022 | Karen A. Cashmere | Chief Commercial Officer | Acquired A | 9,927 | $0.00 | $0 | 28 | Direct |
| 12 Dec, 2022 | Stephen C. Glover | Chief Executive Officer | Acquired A | 448,909 | — | — | 1,283 | Direct |
| 12 Dec, 2022 | Robert G Finizio | Director | Acquired A | 29,781 | $0.00 | $0 | 85 | Direct |
| 12 Dec, 2022 | Peter Wolfe | Chief Financial Officer | Acquired A | 41,585 | — | — | 119 | Direct |
| 12 Dec, 2022 | Min-Chul Park | Director | Acquired A | 29,781 | $0.00 | $0 | 85 | Direct |
| 12 Dec, 2022 | Nicholas A. Jr. Labella | Chief Scientific Officer | Acquired A | 19,854 | $0.00 | $0 | 57 | Direct |